Skip to search formSkip to main contentSkip to account menu

Aldesleukin 22000000 UNT Injection [Proleukin]

Known as: ALDESLEUKIN 1.1 mg in 1 mL INTRAVENOUS INJECTION [PROLEUKIN], Proleukin 22,000,000 UNT Injection, aldesleukin 1.1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Proleukin] 
National Institutes of Health

Related topics

Related topics

8 relations
AldesleukinInjectionMannitolProleukin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
Regulatory T cells (Tregs) play an important role in preventing effector T-cell (Teff) targeting of self-antigens that can lead… 
2016
2016
Abstract 558: Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade
Background: While immune checkpoint blockade is a promising therapeutic approach, combination with agents that modulate… 
2014
2014
OP0104 Low-Dose Interleukin-2 Therapy Caused Selective Expansion of Regulatory T Cells Together with RAPID Reduction of Disease Activity in A Patient with Severe Refractory Sle
Background SLE is characterized by the breakdown of immune tolerance towards nuclear autoantigens. Aberrant activation of… 
2014
2014
Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)
Meeting abstracts To investigate whether the sequence of HD IL-2 and a checkpoint inhibitor, Ipilimumab, will have additive or… 
2014
2014
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
Meeting abstracts To investigate whether the Vemurafenib-induced increased tumor antigen expression, T lymphocyte infiltration… 
2011
2011
Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.
BACKGROUND The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of… 
2004
2004
Comparison of Pharmacokinetics and Pharmacodynamics of two different dosing regimens of Proleukin® (IL-2) in Combination with rituximab: The effect of NK cell expansion.
Background: Published results from studies testing two different dosing regimens of IL-2 in combination with rituximab have shown… 
2004
2004
Investigation of FcγR Polymorphisms and Response to IL-2 (Proleukin®) and Rituximab Treatment in Rituximab-Resistant NHL Patients: Importance of the F/F Polymorphism at Position 158 of the Fcγ.
Background: Antibody-dependent cellular cytotoxicty (ADCC) is an important mechanism of rituximab activity. Genetic polymorphisms… 
2002
2002
Persistierende knotige Lokalreaktion mit Lymphom-ähnlichen Infiltraten nach s.c-Injektion von Interleukin-2
ZusammenfassungInterleukin-2 (IL-2) kommt aufgrund seiner immunstimulatorischen Wirkung auf T-Zellen in der Tumortherapie von… 
1994
1994
Treatment of Patients with Metastatic Renal Cell Carcinoma with Subcutaneous Recombinant Interferon-Alpha 2b and Continuous Infusion of Recombinant lnterleukin-2: A Phase II Study
Background: On the basis of encouraging preclinical data, we investigated the combination of the 2 agents recombinant interferon… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)